Known targets — ChEMBL curated mechanism
CHRM1DRD2DRD3DRD4HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR2APDE3ASIGMAR1SLC9A3
The experimentally established mechanism targets of L-Lactic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 5/20 | 0.42 |
| ▸ | CA4 | P22748 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| L-Lactic Acid SCHEMBL2574910 | 1.00 | — | — | |
| L-Lactic Acid SCHEMBL11294028 | 0.96 | TP53 (0.47) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL3759604 | 0.92 | TP53 (0.50) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL21815670 | 0.92 | TP53 (0.50) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL6709684 | 0.92 | — | — | |
| L-Lactic Acid SCHEMBL19180003 | 0.92 | TP53 (0.50) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL116857 | 0.92 | TP53 (0.50) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL22341771 | 0.92 | TP53 (0.50) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL3767825 | 0.92 | TP53 (0.50) | TP53CA1CA4CA2CYP3A4 | |
| L-Lactic Acid SCHEMBL186171 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240285683-A1 | Compositions And Methods For Enhancing Immunotherapy | THE TRUSTEES OF PRINCETON UNIVERSITY | 2024-08-29 | — | — | US | disclosed |
| US-20230286895-A1 | METHODS FOR PRODUCING ALKYL HYDROXYALKANOATES | CARGILL, INCORPORATED (US) | 2023-09-14 | — | — | US | disclosed |
| US-11691941-B2 | Methods for producing alkyl hydroxyalkanoates | CARGILL, INCORPORATED (US) | 2023-07-04 | — | — | US | disclosed |
| WO-2023081775-A1 | COMBINATION INHIBITORS FOR TREATING FIBROSIS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2023-05-11 | — | — | WO | disclosed |
| CN-115636526-A | Organic pollutant migration and conversion method based on Fe redox enhancement | 中国科学院南京土壤研究所 | 2023-01-24 | — | — | CN | disclosed |
| US-11332428-B2 | Methods for producing alkyl hydroxy alkanoates | CARGILL, INCORPORATED (US) | 2022-05-17 | — | — | US | disclosed |
| US-11332429-B2 | Methods for producing alkyl hydroxyalkanoates | CARGILL, INCORPORATED (US) | 2022-05-17 | — | — | US | disclosed |
| US-20210187023-A1 | Compositions And Methods For Enhancing Immunotherapy | THE TRUSTEES OF PRINCETON UNIVERSITY | 2021-06-24 | — | — | US | disclosed |
| US-20200331839-A1 | METHODS FOR PRODUCING ALKYL HYDROXYALKANOATES | CARGILL, INCORPORATED (US) | 2020-10-22 | — | — | US | disclosed |
| US-10710955-B2 | Methods for producing alkyl hydroxyalkanoates | CARGILL, INCORPORATED (US) | 2020-07-14 | — | — | US | disclosed |
| US-20100062483-A1 | PRODUCTION OF BIO-BASED MATERIALS USING PHOTOBIOREACTORS WITH BINARY CULTURES | BATTELLE MEMORIAL INSTITUTE (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100059436-A1 | SYSTEMS AND METHODS FOR MICROBIAL REDUCTIVE DECHLORINATION OF ENVIRONMENTAL CONTAMINANTS | UNIVERSITY OF MASSACHUSETTS (US) | 2010-03-11 | — | — | US | disclosed |
| EP-1942092-A1 | Preparation of propylene glycol by hydrogenating lactate or lactic acid | Battelle Memorial Institute (US) | 2008-07-09 | — | — | EP | disclosed |
| CN-101074242-A | Cells accumulation for sphosphonate analogs of HIV protease inhibitor compound and the same compound | GILEAD SCIENCES INC (US) | 2007-11-21 | — | — | CN | disclosed |
| CN-1313472-C | Cellular Accumulation of Phosphonate Analogs of HIV Protease Inhibitor Compounds and Such Compounds | GILEAD SCIENCES INC (US) | 2007-05-02 | — | — | CN | disclosed |
| CN-1649885-A | Cellular Accumulation of Phosphonate Analogs of HIV Protease Inhibitor Compounds and Such Compounds | GILEAD SCIENCES INC (US) | 2005-08-03 | — | — | CN | disclosed |
| WO-1999021544-A1 | NOVEL PHARMACEUTICAL ALPHA-KETO CARBOXYLIC ACID COMPOSITIONS, METHOD OF MAKING AND USE THEREOF | UNITED STATES GOVERNMENT, AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1999-05-06 | — | — | WO | disclosed |
| US-5714515-A | Pharmaceutical alpha-keto carboxylic acid compositions, method of making and use thereof | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1998-02-03 | — | — | US | disclosed |
| WO-1997041848-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING ALPHA-KETO CARBOXYLATES | THE GOVERNMENT OF THE UNITED STATES, REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1997-11-13 | — | — | WO | disclosed |
| US-5536751-A | PHOSPHORYLATION POTENTIAL | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1996-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240285683-A1 | Compositions And Methods For Enhancing Immunotherapy | RNASE1, DERA, SLC2A1 | TP53 82/4885CA1 347/4885CA4 397/4885 |
| US-20210187023-A1 | Compositions And Methods For Enhancing Immunotherapy | RNASE1, DERA, SLC2A1 | TP53 82/4885CA1 347/4885CA4 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.